Ron Frieson - Jun 8, 2022 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
Director
Signature
/s/ Carolyn Rucci, attorney-in-fact for Ronald E. Frieson
Stock symbol
AKBA
Transactions as of
Jun 8, 2022
Transactions value $
$0
Form type
4
Date filed
6/9/2022, 04:57 PM
Previous filing
Nov 3, 2021
Next filing
Jun 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Award $0 +13.7K $0.00 13.7K Jun 8, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKBA Stock Option (Right to buy) Award $0 +20.1K $0.00 20.1K Jun 8, 2022 Common Stock 20.1K $0.45 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"), as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.
F2 The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2014 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.